Melanoma, the most aggressive form of skin cancer, presents a major clinical challenge due to its tendency to metastasize and recalcitrance to traditional therapies. Despite advances in surgery, chemotherapy, and radiotherapy, the outlook for advanced melanoma remains bleak, reinforcing the urgent need for more effective treatments. Photodynamic therapy (PDT) has emerged as a promising alternative, leading to targeted tumor destruction with minimal harm to surrounding tissues. In this study, the direct and abscopal antitumor effects of PDT in a bilateral murine melanoma model were evaluated. Although only one of the two tumors was treated, effects were observed in both. Our findings revealed significant changes in systemic inflammation and alterations in CD4 and CD8 T cell populations in treated groups, as evidenced by blood analyses and flow cytometry. High-throughput RNA sequencing (RNA-Seq) further unveiled shifts in gene expression profiles in both treated and untreated tumors. This research sheds light on the novel antitumor and abscopal effects of nanoemulsion of aluminum chloride phthalocyanine (AlPcNE)-mediated PDT in melanoma, highlighting the potential of different PDT protocols to modulate immune responses and to achieve more effective and targeted cancer treatments.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11435272PMC
http://dx.doi.org/10.3390/pharmaceutics16091177DOI Listing

Publication Analysis

Top Keywords

direct abscopal
8
abscopal antitumor
8
photodynamic therapy
8
murine melanoma
8
melanoma model
8
melanoma
5
antitumor responses
4
responses elicited
4
elicited alpcne-mediated
4
alpcne-mediated photodynamic
4

Similar Publications

Stereotactic Body Therapy for Urologic Cancers-What the Urologist Needs to Know.

Life (Basel)

December 2024

Department of Surgery, Peter MacCallum Cancer Centre, The University of Melbourne, Parkville, VIC 3052, Australia.

Background: stereotactic ablative body radiotherapy (SABR) is a disruptive radiation therapy technique which is increasingly used for the treatment of urologic cancers. The aim of this narrative review is to provide an overview on the current landscape of SABR in urologic cancers and highlight advancements on the horizon.

Methods: a narrative review of the contemporary role of SABR in urologic cancers is conducted.

View Article and Find Full Text PDF

Objective: Immunotherapeutic inhibition of PD-1 by systemically administered monoclonal antibodies is widely used in cancer treatment, but it may cause severe immune-related adverse events (irSAEs). Neoadjuvant PD-1 inhibition before surgery has shown promise in reducing recurrence by stimulating durable antitumor immunity. Local intratumoral (IT) immunotherapy is a potential strategy to minimize irSAEs, but antibodies have limited tumor penetration, making them less suitable for this approach.

View Article and Find Full Text PDF

Durable antitumor response via an oncolytic virus encoding decoy-resistant IL-18.

J Immunother Cancer

December 2024

State Key Laboratory of Biotechnology, Medical School, Nanjing University, Nanjing, China

Article Synopsis
  • Interleukin-18 (IL-18) enhances immune responses, but its clinical use is limited by a decoy receptor; to overcome this, researchers developed a variant called DR18 that doesn't bind to IL-18 binding protein.
  • They tested this DR18 variant using an oncolytic adenovirus (oAdDR18) in mouse models of different tumors to see its effects on tumor growth and immune response.
  • Results showed that oAdDR18 led to significant tumor growth reduction and enhanced immune cell infiltration compared to other forms of IL-18, indicating strong potential for treating cancers and reducing metastasis.
View Article and Find Full Text PDF

Effective disruption of cancer cell membranes by photodynamic therapy with cell membrane-adhesive photosensitizer.

J Clin Biochem Nutr

November 2024

Department of Gastroenterology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Ibaraki 305-8575, Japan.

Photodynamic therapy (PDT) is a noninvasive cancer treatment modality that involves the administration of photosensitizers and light irradiation. Previously, we established a polycation-containing hematoporphyrin (aHP) formulation that demonstrated superior antitumor efficacy , than the original hematoporphyrin (HP). In this study, we investigated underlining mechanisms of the high antitumor effect of aHP using cell experiments.

View Article and Find Full Text PDF

Recent advances in immunotherapy for small cell lung cancer.

Curr Opin Oncol

January 2025

Department of Radiation Oncology and Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.

Article Synopsis
  • - Recent advances in immunotherapy for small cell lung cancer (SCLC) highlight immune checkpoint inhibitors (ICIs) as the new standard first-line treatment for extensive-stage SCLC, bolstered by the ADRIATIC trial emphasizing ICI maintenance therapy.
  • - Combining radiotherapy with ICIs has shown promising results, and ongoing studies are exploring ICI combinations with targeted therapies, including the newly FDA-approved tarlatamab for second-line treatment of extensive-stage SCLC.
  • - Despite these improvements, the overall clinical benefits of immunotherapy in SCLC remain modest, indicating a need for more research to optimize treatment strategies and enhance effectiveness.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!